



Erratum

Erratum on “Eltrombopag as first-line treatment in severe aplastic anemia: a cost-effectiveness analysis from the Brazilian public healthcare system perspective”

M.A. Salvino ^{a,b}, C. Bonfim ^c, R.T. Calado ^d, H. Kim ^e, J.F. Bertinato ^e,
P. Scheinberg ^f

^a Hospital Universitário Professor Edgar Santos (HUPES), Universidade Federal da Bahia (UFBA), Salvador, BA, Brazil

^b Hospital São Rafael, Instituto D’Or de Ensino e Pesquisa (IDOR), Salvador, BA, Brazil

^c Blood and Marrow Transplantation Unit, Department of Hematology, Hospital de Clínicas da Universidade Federal do Paraná (UFPR), Curitiba, PR, Brazil

^d Department of Medical Imaging, Haematology, and Clinical Oncology, Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil

^e Novartis Biociências S.A., São Paulo, SP, Brazil

^f Division of Hematology, A Beneficência Portuguesa de São Paulo (BP), São Paulo, SP, Brazil

ARTICLE INFO

Article history:

Available online 12 April 2022

In the abstract “Eltrombopag as first-line treatment in severe aplastic anemia: a cost-effectiveness analysis from the Brazilian public healthcare system perspective”, published in Hematol Transfus Cell Ther. 2021;43(S1):S1–S546, <https://doi.org/10.1016/j.htct.2021.10.063>

Where it reads:

“The combination of eltrombopag plus IST showed a higher cost of treatment than IST alone (R\$ 248,964.02 vs. R\$ 132,695.59, respectively)”

It should read:

“The combination of eltrombopag plus IST showed a higher cost of treatment than IST alone (R\$ R\$ 230,035 vs. R\$ 134,033, respectively)”

Where it reads:

“This resulted in an incremental cost of R\$ 116.268 per patient treated with IST alone.”

It should read:

“However, the combination saved resources related to HSCT, relapse and end of life. This resulted in an incremental cost of R\$ 96,002 per patient treated with IST alone.”

Where it reads:

“resulting in an ICER of R\$ 83.412 per life-year gained.”

it should read:

“resulting in an ICER of R\$ 68,872 per life-year gained.”

<http://dx.doi.org/10.1016/j.htct.2021.10.063>

<https://doi.org/10.1016/j.htct.2022.04.001>

2531-1379/© 2022 Published by Elsevier Espana, S.L. on behalf of Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular..